bimekizumab
Trade name: Bimzelx
mAbapproved
Approved
Oct 17, 2023
Bimekizumab, sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa. — Wikipedia
Clinical trial activity
52 trials · 13 clinical orgs · 1 marketing orgs
Phase 1
11
Phase 2
40
Phase 3
24
Phase 4
2
Earliest trial started Nov 1, 2012 (NCT02529956)
Timeline
Indications
Approved for
Studied for
- Arthritis · Phase 3
- Arthritis, Juvenile · Phase 3
- Arthritis, Psoriatic · Phase 4
- Arthritis, Rheumatoid · Phase 2
- Axial Spondyloarthritis · Phase 3
- Dermatitis, Atopic · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Hidradenitis Suppurativa · Phase 3
- Non-Radiographic Axial Spondyloarthritis · Phase 3
- Psoriasis · Phase 4
- Rheumatic Diseases · Phase 2
- Spondylitis, Ankylosing · Phase 3
Mechanism of action
- Interleukin 17AINHIBITOR
IL17A inhibitor
- Interleukin-17FINHIBITOR
Interleukin-17F inhibitor
Approval history
- approvedOct 17, 2023
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaBimekizumab ↗
- ChEMBLCHEMBL5314834 ↗
- ChEMBLCHEMBL4297700 ↗
Also known as
- bimekizumab
- bimekizumab
- ucb4940
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07277660 | Phase 2 | Dec 31, 2025 | UCB |
| NCT07290036 | Phase 1 | Dec 31, 2025 | UCB |
| NCT07219420 | Phase 3 | Nov 30, 2025 | UCB |
| NCT06888193 | Phase 1 | Oct 31, 2025 | UCB |
| NCT07138898 | Phase 2 | Sep 30, 2025 | New York University |
| NCT06921850 | Phase 3 | Apr 7, 2025 | UCB |
| NCT06668181 | Phase 3 | Oct 31, 2024 | UCB |
| NCT06624228 | Phase 3 | Oct 31, 2024 | UCB |
| NCT06506916 | Phase 3 | Jul 12, 2024 | UCB |
| NCT06315335 | Phase 1 | Jul 1, 2024 | UCB |
| NCT06425549 | Phase 3 | Jun 25, 2024 | UCB |
| NCT06336343 | Phase 4 | Jun 3, 2024 | Icahn School of Medicine at Mount Sinai, UCB, Windsor Dermatology |
| NCT06011733 | Phase 3 | Oct 31, 2023 | UCB |
| NCT05499416 | Phase 4 | Sep 30, 2022 | Ciusss de L'Est de l'Île de Montréal, Innovaderm |
| NCT05292131 | Phase 1 | Mar 17, 2022 | UCB |
| NCT05020249 | Phase 3 | Sep 27, 2021 | UCB |
| NCT04901195 | Phase 3 | May 27, 2021 | UCB |
| NCT04718896 | Phase 2 | Apr 6, 2021 | UCB |
| NCT04643457 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2020 | UCB |
| NCT05162937 | Phase 2 | Sep 7, 2020 | Government of China |
Showing 20 of 52 trials
Page 1 / 3
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| UCB | For profit | 41 | 40 | 4 | 2016 |
| Hoosier Cancer Research Network | Academic/Hospital | 8 | 8 | 2 | 2012 |
| Parexel | For profit | 3 | 0 | 2 | 2014 |
| ARENSIA, Moldova | For profit | 1 | 0 | 1 | 2014 |
| Ciusss de L'Est de l'Île de Montréal | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Comac Medical | For profit | 1 | 0 | 1 | 2014 |
| Government of China | Government | 1 | 1 | 1 | 2020 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Innovaderm | For profit | 1 | 1 | 1 | 2022 |
| MAC Clinical Research | For profit | 1 | 0 | 1 | 2014 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2015 |
| Windsor Dermatology | Academic/Hospital | 1 | 0 | 1 | 2024 |
13 organizations
Page 1 / 1